An initial set of 249 amino-acids sequences, encoding putative transaminases, was obtained by BLAST analysis of KES23360 at Uniprot. 1 An MSA for the amino-acid sequences was inferred using MAFFT 2 (v. 7.043; MAFFT was chosen because of its accuracy 3, 4 ), and Seaview was used to visualise the alignment (v. 4.4.1).
Subcloning, Expression and Purification
Synthetic genes corresponding to the six ancestral proteins were cloned in the same manner as the KES23360 transaminase protein. Each gene was obtained as an E. coli codon-optimised synthetic gene in pMA-RQ vector 8 (Invitrogen). DNA for each gene, and the desired expression vector, pETcc2, was digested using NdeI and BamHI restriction endonucleases (NEB), separated using a 0.8% agarose gel and purified using a Gel Extraction Kit and following the Manufacturer's Guidelines (Macherey Nagel). Linear gene and vector fragments were ligated using T4 DNA ligase (NEB) and the DNA was transformed into E. coli BL21 λDE3 electrocompetent cells by electroporation. Visualised transformants were used to inoculate 10 mL LB medium containing ampicillin (100 μg/mL) and grown overnight at 37 °C with shaking. DNA was isolated using a Bioline Miniprep Kit following manufacturers guidelines and sequenced to validate the final construct for each gene (Macrogen, S. Korea).
Protein overexpression was achieved by growing 500 mL of E. coli BL21 λDE3 containing the desired vector in LB media containing ampicillin (100 μg/mL) at 37°C. When the OD600 reached 0.6-1.0, the cultures were induced by the addition of IPTG (Isopropyl β-D-1-thiogalactopyranoside; 1 mM final concentration) and further incubated at 15 °C for 18 hours. The cells were isolated by centrifugation (4000 x g; 20 minutes) and the supernatant discarded. The pellet was resuspended in imidazole/sodium chloride/potassium phosphate buffer (5 mM/500 mM/10 mM, pH 7.5) and cell lysis was achieved using an Avestin C3 Emulsiflex Homogeniser at 20 kPSI. Cellular debris was pelleted by centrifugation (40,000 x g, 45 minutes) and the supernatant was passed over a HiTrap Chelating HP column (GE Healthcare) on an Åkta FPLC (Fast Protein Liquid Chromatography, GE Healthcare) Protein was eluted with an increasing concentration of imidazole (5-500 mM) and the separated protein was transferred into potassium phosphate buffer (10 mM, pH 7.5), concentrated by centrifugation (GE Healthcare; 10k MWCO) and further purified by gel filtration (Superdex 200; G.E. Healthcare) in the same phosphate buffer. Purity was estimated to be >95% by SDS-PAGE.
Crystallography
All protein samples were analysed for buffer preference and stability using DSF. 9 Table S1 shows stability values for KES23360 and ancestral proteins, based on triplicate melt curves.
Initial crystallisation trials were performed with the KES23360 protein. The protein sample (5 mg/mL in 10 mM KPO4 buffer, pH 7.5) was used in initial screens (JCSG+, PACT, PS gradient -for details of screens see http://c6.csiro.au). Drops were set up with 200 nL protein mixed with 200 nL reservoir solution and equilibrated against 50 μL of reservoir in SD-2 plates (Molecular Dimensions, UK). Yellow, blunt ended hexagonal bipyramidal crystals grew out of conditions containing 2 M ammonium sulfate at 8 C. The initial conditions were refined by screening around the initial condition, and by additive optimisation. Each of the ancestral peptides was first screened as supplied (conditions shown in Table  S2 ) in the JCSG screen at 20 °C. The ancestral peptides were transferred into different buffer formulations, based on the results of the DSF experiments, and the reformulated proteins were screened under the optimum conditions determined from the crystal screening, with and without seeding. Seeds from the N16 protein were used for all of the ancestral peptides. Final crystallisation conditions for each of the six ancestral peptides, along with the buffer formulations used, are shown in Table S2 .
Crystals were cryoprotected and frozen in liquid nitrogen before data collection at the Australian Synchrotron. The KES23360 data set was collected using 0.5° oscillations due to the long unit cell, whereas the ancestral peptide data sets were collected using 1.0° oscillations. Full datasets were obtained by collecting either 180° or 360° depending on the space group (X-ray data is shown in Table  S2 ). Data were indexed using XDS 10 and scaled using Aimless. 11 The KES23360 structure was solved using PDB code 3GJU as the molecular replacement model in Phaser 12 and all other structures were solved using Phaser with KES23360 as the model. The models were rebuilt manually in Coot 13 and refined using Refmac. 14 KES23360 was cryoptotected with glycerol. N16, N43 and N48 were cryoprotected with AP/E core 150; N6, N15 and N17 were cryoprotected with the reservoir solution (which contained glycerol) and supplemented with additional glycerol to a final concentration of 25%.
Activity Assays
Transaminases were assayed using previously described methods. 15 Activity for each of the transaminases was assessed using enzyme-coupled dehydrogenase assays. A typical assay comprised: 6.25 mM substrate, 0.5 mM pyruvate, 1.25 mM nicotinamide adenine dinucleotide (NAD + ), 0.035 U of alanine dehydrogenase (ADH; where 1 U corresponds to the amount of enzyme which converts 1 μmol L-alanine per minute at pH 10.0 and 30°C), 2 -50 nM transaminase, potassium phosphate (100 mM, pH 10). The rates of the transaminases were inferred from the coupled rate of NAD + turnover by alanine dehydrogenase, which was dependent on the production of co-product (alanine) by the transaminase. NAD + turnover was measured by the change in UV absorbance at 340 nm using a SpectraMax M2 spectrophotometer (Molecular Devices, Australia); reactions were conducted at 28°C
. Kinetic parameters were obtained using the above method, recording initial rates of activity across a range of substrate concentrations. Parameters were subsequently calculated using non-linear regression.
Molecular Dynamics Simulations
Models of KES23360, N6 and N43 were prepared in Accelrys Discovery Studio v 3.5 from the experimentally derived structure as a starting point. A model for the HMD:PLP external aldimine intermediate and PLP (for N43) were created in Accelrys Discovery Studio v 3.5 and prepared for MD using the Full Minimization tool in Discovery Studio v 3.5 using the default settings (CHARMm forcefield). HMD-PLP aldimine complexes were manually orientated in the active site using the electron density from native PLP as a guide. For N43 no PLP was solved in the initial X-ray structure, so this was constructed in silico and manually orientated based on alignment against KES23360 and N16. Atomic charges were calculated in Accelrys Materials Studio v8.0 using the QEq method and the substrates were manually docked into the active site. Ligands were prepared for MD in AMBER 14 16 using the GAFF forcefield and the protein models were solvated in a TIP3P octahedral solvent box with a minimum 12 Å periodic boundary distance and charge-neutralised by the addition of Na + ions. Proteins were prepared using the ff99sb forcefield.
Initial minimisation of both systems was performed using AMBER 14 over 10,000 steps under a constant pressure of 1 Bar. Bonds lengths on bonds involving hydrogen were constrained in SHAKE and force evaluation on these bonds was not performed. 200 ns MD simulations with a step-size of 0.002 ps were performed at 310 K and 1 bar pressure with a 2 ps relaxation time. Trajectories were analysed using VMD (v. 1.9.2) 17 . Analysis was conducted on 150 ns of the simulation, removing the first 50 ns to ensure the systems had equilibrated as determined through RMSD analysis. KES23360  MTDYAKLFEQDRAHFMHPSTHAHDHASGALPGRIITGASGVRIRDHQGRELLDAFAGLYC  N6  MTDFDQLFEQDRAHFMHPSTHAHDHASGALPGRIITGASGIRIRDHEGRELIDAFAGLYC  N15  MTDLDQLFEMDRAHFMHPSTHAHDHASGALPGRIITGGKGIRIQDHEGREYIDAFAGLYC  N16  MQSLDQLFEMDRAHFMHPSTHAHDHASGALPGRIITGGKGIRIEDHEGREYIDAFAGLYC  N17  MTSLDQLFEEDRAHFMHPSTHAHDHASGALPGKIVTGGKGIRIEDHQGREYIDAFAGLYC  N43  MTSLEQLLEMDRAHFMHPSTHAYDHASGALPGRIITGGKGIRIEDHEGREYIDAFAGLYC  N48 MTDTDDLLEMDRAHFFHPSTHLRDHASGELPGRIITGGKGIRIQDSEGREYIDAFAGLYC * . .*:* *****:***** ***** ***:*:**..*:**.* :*** :******** KES23360 VNIGYGRLEVADAIHEQAKQLAYYHTYVGHASEAIIELSARIIRDWAPAGMKKVYYGLSG N6 VNIGYGRTEVADAIYKQAKELAYYHTYVGHSTEAIIELSSRIIRDWAPAGMKKVYYGLSG N15 VNIGYGRTEVADAIYEQAKELAYYHTYVGHSTEAIIELSSRIIRDWAPAGMKKVYYGMSG N16 VNIGYGRTEVADAIYEQAKQLAYYHTYVGHSTDAIIELSSRIIRDWAPAGMKKVYYGMSG N17 VNIGYGRTEVADAIYEQAKQLAYYHTYVGHSTDAIIELSSRIIRDWAPAGMKKVYYGMSG N43 VNIGYGREEVADAIYEQAKQLAYYHTYVGHSNDPVIELSSRIIEDWAPAGMKKVFYGMSG N48 VNVGYGRTEIADAIYEQAKELAYYHTYVGHSNEPIIELSERIIREWAPAGMSKVYYGMSG **:**** *:****::***:**********:.: :**** ***.:******.**:**:* *   KES23360  SDANETQVKLVRYYNNVLGRPQKKKIISRQRGYHGSGIVTGSLTGLASFHQHFDLPVEGV  N6  SDANETQIKLVRYYNNVLGRPQKKKIISRQRGYHGSGIMTGSLTGLPSFHQHFDLPVEGI  N15  SDANETQIKLVWYYNNVLGRPQKKKIISRQRGYHGSGIMTGSLTGLPSFHQHFDLPIERI  N16  SDANETQIKLVWYYNNVLGRPNKKKIISRERGYHGSGIVTGSLTGLPSFHQHFDLPIDRV  N17  SDANETQIKIVWYYNNVLGRPNKKKIISRERGYHGSGIVTGSLTGLPSFHQHFDLPIDRV  N43  SDANETQIKLVWYYNNVLGRPNKKKIIARERSYHGSGIVTGSLTGLPSFHQHFDLPIDRV  N48 SDANETQIKLVWYYNNVLGRPQKKKIISRQRGYHGSGIMTGSLTGLPAFHNHFDLPLEPI *******:*:* *********:*****:*:*.******:******* :**:*****:: :   KES23360  KHTLCPHFYKAPAGMDEAAFVRHCAQELENLILAEGPDTVAAFIGEPVMGTGGIIVPPKG  N6  KHTVCPHWYKAPAGMDEAAFVRYCADELEKLILAEGPDTVAAFIGEPVMGTGGIIVPPKG  N15  KHTVCPHWYKAPAGMSEAQFVRYCADELEKLILAEGPDTVAAFIGEPVMGTGGIIPPPQG  N16  KHTVCPHWYRAPAGMSEAQFVAYCVEELEKLIAREGADTIAAFIAEPVMGTGGIIPPPQG  N17  KHTVCPHWYKAPAGMSEAQFVAYCVEELEKLIAREGADTIAAFIAEPVMGTGGIIAPPQG  N43  KHTVCPHWYNAPPGMSEAQFVAYCVEELEKLIAREGADTIAAFIAEPVMGTGGIVPPPQG  N48 RHTTCPHYYRAPAGMSEAEFSRHCADELEKMILAEGPDTVAAFIGEPVMGTGGIVPPPEG :** ***:*.** **.** * :*.:***::* ** **:****.*********: **:* KES23360  YWEAIQAVLAKYDVLLIADEVVCAFGRLGDKMGSQRHAMRPDLITTAKGLTSAYAPLSAV  N6  YWEAIQAVLNKYDVLLIADEVVCAFGRLGSKMGSQRYGMRPDLITTAKGLTSAYAPLSAV  N15  YWEAIQAVLNKYDILLIADEVVCGFGRLGSKMGSQHYGMKPDLITVAKGLTSAYAPLSGV  N16  YWEAIQAVLRKHDILLIADEVVCGFGRLGSKMGSQHYGIKPDLITVAKGLTSAYAPLSGV  N17  YWEAIQAVLRKHDILLISDEVVCGFGRLGSKMGAQHYGIKPDLITVAKGLTSAYAPLSGV  N43  YWEAIQAVLRKHDILLIADEVVCGFGRLGSKTGSEHYGIKPDLITVAKGLTSAYAPLSAV  N48 YWEAIQAVLNKYDILLIADEVVCGFGRTGSMFGSHHYGMKPDLITVAKGLTSAYAPLSGV ********* *:*:***:*****.*** *. *:.::.::*****.************.* KES23360  IVGEKVWDVIDSASTREGAMGHGWTYSGHPICAAAALANLDILERENITANAADVGGYLN  N6  IVGEKVWDVIEKASQKEGAMGHGWTYSGHPICAAAALANLDILERENLTANAADVGAYLN  N15  IVGEKVWDVIEKGSQEHGPMGHGWTYSGHPICAAAALANLDILERENLTGNAADVGAYLQ  N16  IVGEKVWDVIEKGSQEHGPMGHGWTYSGHPICAAAALANLDILERENLTGNAADVGAYLQ  N17  IVGEKVWDVIEKGSQEHGPMGHGWTYSGHPICAAAALANLDILERENLTGNAADVGAYLQ  N43  IVSEKVWDVIEKGSREHGVMGHGWTYSGHPVCAAAALANLDILERENLTGNAADVGAYLQ  N48 IVGEKVWKVLEQGSDQYGPIGHGWTYSGHPICAAAALANLDIIERENLTGNAADTGAYFQ **.****.*::..* . * :**********:***********:****:*.****.*.* ::   KES23360  QQLRQAFEGHPLVGEVRGDGMLAALEFMADREARTPFDAALKVGPKVSAACLERGMIARA  N6  QRLRETFEGHPLVGEVRGDGMLAALEFMADREARTPFDPALKVGPKVSAACLEDGMIARA  N15  QRLRETFGGHPLVGEVRGVGMLAALEFMADKDARTPFDPALKVGPKVSAACLEDGMIARA  N16  QRLHEAFGAHPLVGEVRGVGMLAALEFMADKDARTPFDPALKVGPKVSAAALEDGMIARA  N17  QRLHEAFGAHPLVGEVRGVGMLAALEFMADKDARTPFDPALKVGPKVSAAALEDGVIARA  N43  QRLHEAFGAHPLVGEVRGVGMLAALEFMADKGARTPFDPALKVSQKVAAAALEDGLIVRA  N48 QRMRETFGDHPLVGEVRGVGLMAALEFVADKDKRTRFDPSLKVGPRVSAACLEDGMIARA *:::::* ********* *::*****:**: ** ** :***. :*:**.** *:*.* *   KES23360  MPHGDILGFAPPLVLSRAEADEVVGIAKAAVDAVAAEVL  N6  MPHGDILGFAPPLVLTRAEADEIVGIAKAAVDEVAGEVL  N15  MPHGDILGFAPPLVITRAEVDEIVGIAKQAVDEVADEVL  N16  MPHGDILGFAPPLVTTRAEVDEIVGIAKQAVDEVADEVL  N17  MPHGDILGFAPPLVTTRAEVDEIVGIVKQAVDEVADEVL  N43  LPHGDILGFAPPLVTTRAEVDEIVAIAKEAFDEVADAVL  N48 MPHGDILGFAPPLVITRAEVDEIVDIAKQAVDAVADELV :************* :***.**:* *.* *.* ** :: Figure S3 -The X-ray crystal structure of KES23360 (PDB accession number 5KQT) shown as a monomer (top left) and dimer (top right). The protein is shown in a cartoon representation with the pyridoxal-5'-phosphate (PLP) cofactor shown in stick representation. Bottom -an overlay of the seven proteins illustrating the high overall structural conservation between the proteins. 
